Haemodynamic Effects of Withdrawal of Long-Term Treatment with β-Adrenoceptor Blocking Agents in Subjects with Essential Hypertension

1981 ◽  
Vol 61 (s7) ◽  
pp. 421s-423s ◽  
Author(s):  
C. Bengtsson ◽  
Y. Larsson ◽  
V. Panfilov ◽  
R. Sivertsson ◽  
H. Åström
Keyword(s):  
Blood Pressure ◽  
Cardiac Output ◽  
Essential Hypertension ◽  
Structural Changes ◽  
Peripheral Resistance ◽  
Blocking Agent ◽  
Term Treatment ◽  
First Year ◽  
Long Term Treatment

1. After 10 years of β-adrenoceptor blockade in five female patients with essential hypertension, the β-adrenoceptor-blocking agent was withdrawn, and the women were then followed up for 1 year, with measurements of cardiac output and peripheral resistance. 2. Blood pressure remained low during the first year after withdrawal in spite of the fact that the heart rate increased within the first few days. 3. Cardiac output was found to increase during the first year after withdrawal, although total peripheral resistance was essentially unchanged. 4. The maintenance of low blood pressure after withdrawal of the antihypertensive drug might indicate a regression of structural changes in the resistance vessels during successful long-term antihypertensive treatment. 5. Minimal resistance in hands and calves did not increase during the year after withdrawal.

Increased Plasma Noradrenaline Concentrations in Essential Hypertension and Their Decrease after Long-Term Treatment with a β-Receptor-Blocking Agent (Prindolol)

1976 ◽  
Vol 51 (s3) ◽  
pp. 485s-488s ◽  
Author(s):  
H. M. Brecht ◽  
F. Banthien ◽  
W. Ernst ◽  
W. Schoeppe
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Nervous Activity ◽  
Blocking Agent ◽  
Term Treatment ◽  
Plasma Noradrenaline ◽  
Sympathetic Nervous Activity ◽  
Control Subjects ◽  
Long Term Treatment

1. Plasma noradrenaline was measured in fiftynine patients with mild to severe essential hypertension and in fifteen normotensive control subjects under basal and orthostatic conditions. 2. In patients with essential hypertension mean plasma noradrenaline concentrations were significantly higher than in control subjects under basal and orthostatic conditions. 3. In patients with essential hypertension basal diastolic blood pressure correlated closely with the corresponding plasma noradrenaline concentrations. 4. Long-term treatment with prindolol of patients with essential hypertension led to a significant fall in diastolic and systolic blood pressure and heart rate and to a significant decrease in plasma noradrenaline concentrations under basal and orthostatic conditions. 5. The adrenergic response to upright posture, reflected by an increase in plasma noradrenaline, was not abolished by prindolol. 6. It is concluded that the anti-hypertensive effect of prindolol in patients with essential hypertension is at least partially mediated by a decrease of sympathetic nervous activity.

Clinical and Haemodynamic Study of Atenolol (Tenormin) in Essential Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 525s-526s
Author(s):  
H. Æ. Jensen ◽  
K. Rasmussen ◽  
N. Mosbæk
Keyword(s):  
Blood Pressure ◽  
Cardiac Output ◽  
Essential Hypertension ◽  
Side Effects ◽  
Total Peripheral Resistance ◽  
Peripheral Resistance ◽  
Blocking Agent ◽  
Pronounced Decrease ◽  
Daily Range ◽  
Haemodynamic Study

1. The β1-adrenoreceptor-blocking agent atenolol was studied in the treatment of twelve out-patients with essential hypertension. 2. With a mean dose of 110 mg of atenolol daily (range 75–200 mg/day) we observed a pronounced decrease in blood pressure. 3. Only minimal side effects were seen. 4. Cardiac output decreased from 4·6 to 3·4 l/min during treatment. This decrease did not correlate with the decrease in blood pressure but correlated well with the changes in calculated total peripheral resistance.

Interaction of Dopamine, Methyldopa and Reserpine in the Sympatho-Adrenal System in Essential Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 461s-463s
Author(s):  
K. Abe ◽  
H. Aoyagi ◽  
M. Yasujima ◽  
S. Miyazaki ◽  
T. Kusaka ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Peripheral Nerve ◽  
Pressor Response ◽  
Normal Subjects ◽  
Term Treatment ◽  
Adrenal System ◽  
Long Term Treatment ◽  
Depressor Effect

1. The interactions of dopamine, reserpine and methyldopa on blood pressure of normal subjects and of those with essential hypertension were examined. 2. When biosynthesis of noradrenaline from dopamine was blocked by reserpine, dopamine induced a prominent depressor effect in essential hypertension. 3. The long-term treatment with methyldopa induced a marked potentiation of the pressor action of domapine in hypertension, although no significant pressor response was found in normal subjects. 4. It is suggested that methylnoradrenaline may accumulate in peripheral nerve endings of patients with essential hypertension in comparison with normal subjects, and this accumulated methylnoradrenaline potentiates the pressor response to dopamine in essential hypertension.

Long-Term Treatment of Essential Hypertension with Nadolol and Hydrochlorothiazide: A Two-Year Follow-Up

1982 ◽  
Vol 10 (2) ◽  
pp. 87-91 ◽  
Author(s):  
M M El-Mehairy ◽  
A Shaker ◽  
M Ramadan ◽  
S Hamza ◽  
S S Tadros
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Combined Therapy ◽  
Term Treatment ◽  
Once Daily ◽  
Supine Blood Pressure ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Adrenergic Blocker

After 3 weeks of placebo administration, thirty-two mildly or moderately hypertensive patients were treated with hydrochlorothiazide (HCZ) for 3 weeks, then with HCZ plus nadolol, a new beta-adrenergic blocker, for 2 years. The dose of HCZ was 50 mg once daily for all except two patients, who received 50 mg twice a day. The dose of nadolol ranged from 40 mg to 240 mg, once daily. The average supine blood pressure decreased from 182/110 mm Hg at the end of the placebo period to 170/104 mm Hg at the end of treatment with HCZ alone. Nadolol was added to the regimen, and the average supine blood pressure decreased further to 132/88 mm Hg at the end of 3 months of combined therapy. It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed. Side-effects were mild, and none required a change in dosage. A once-daily dose of nadolol combined with HCZ appears to be safe and effective therapy for the long-term treatment of mild or moderate essential hypertension.

Terazosin, A New Selective  1-Adrenergic Blocking Agent: Results of Long-Term Treatment in Patients with Essential Hypertension

1988 ◽  
Vol 1 (3 Pt 3) ◽  
pp. 237S-240S ◽  
Author(s):  
R. R. Luther ◽  
H. N. Glassman ◽  
C. B. Estep ◽  
P. J. Schmitz ◽  
J. K. Horton ◽  
...  
Keyword(s):  
Essential Hypertension ◽  
Blocking Agent ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Adrenergic Blocking

Long-term hemodynamic actions of atrial natriuretic factor (99-126) in conscious sheep

1988 ◽  
Vol 254 (4) ◽  
pp. H811-H815 ◽  
Author(s):  
D. G. Parkes ◽  
J. P. Coghlan ◽  
J. G. McDougall ◽  
B. A. Scoggins
Keyword(s):  
Blood Pressure ◽  
Cardiac Output ◽  
Stroke Volume ◽  
Blood Volume ◽  
Total Peripheral Resistance ◽  
Atrial Natriuretic Factor ◽  
Peripheral Resistance ◽  
Natriuretic Factor ◽  
Atrial Natriuretic

The hemodynamic and metabolic effects of long-term (5 day) infusion of human atrial natriuretic factor (ANF) were examined in conscious chronically instrumented sheep. Infusion of ANF at 20 micrograms/h, a rate below the threshold for an acute natriuretic effect, decreased blood pressure by 9 +/- 1 mmHg on day 5, associated with a fall in calculated total peripheral resistance. On day 1, ANF reduced cardiac output, stroke volume, and blood volume, effects that were associated with an increase in heart rate and calculated total peripheral resistance and a small decrease in blood pressure. On days 4 and 5 there was a small increase in urine volume and sodium excretion. On day 5 an increase in water intake and body weight was observed. No change was seen in plasma concentrations of renin, arginine vasopressin, glucose, adrenocorticotropic hormone, or protein. This study suggests that the short-term hypotensive effect of ANF results from a reduction in cardiac output associated with a fall in both stroke volume and effective blood volume. However, after 5 days of infusion, ANF lowers blood pressure via a reduction in total peripheral resistance.

Sign in / Sign up

Export Citation Format

Share Document